Board of Directors

William Larkins, PhD, Chief Executive Officer and Director

William (Bill) has nearly 30 years of experience in the pharmaceutical industry. Prior to joining Custopharm and creating Leucadia Pharmaceuticals, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Prior to Bedford Laboratories he held various scientific leadership positions at Amylin, Novartis, ESI-Lederle, and Barr Laboratories. He began his career as an analytical research chemist at Zeneca Pharmaceuticals. Bill holds a PhD degree in Analytical Chemistry from The Ohio State University and a Bachelor of Science degree in Chemistry from Purdue University.

Al Heller, Chairman

Al Heller is the former president and CEO of American Pharmaceutical Partners Inc. (APPI), a leading manufacturer of multi-source and branded injectable pharmaceutical products. He also was senior vice president and president of Global Renal Operations for Baxter International, where he led global operations for the Renal and Transfusion Therapies divisions, global manufacturing and the Office of the Chief Scientific Officer. Al began his career at G.D. Searle. During his 23 years with the company, he was promoted to numerous positions, including co-president and COO, and executive vice president and president of Searle Operations. Al currently serves as an operating partner with Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He received his bachelor’s degree from the University of Illinois, Chicago and his master’s degree in business administration from DePaul University.

Dave McCleary, Vice Chairman

Dave is the co-founder of Custopharm, Inc, currently serving as Vice Chairman of the Board. Accomplished pharmaceutical executive with 33 years of experience encompassing executive management and strategic business development in a growing and changing global environment. Outstanding record of leadership and achievement in enhancing productivity, reducing costs and increasing profitability, successfully managed sales departments at Warner Lambert, Regis Technologies, Inc., Chemwerth, Inc., and Custopharm, Inc. David holds a Bachelor of Business Administration from the Iowa State University.

Dan Robins, PhD, Director

Dan Robins is former vice president of global development for Mylan, where he was responsible for injectable products. His former business, Bioniche Pharma, where he led research and development in Ireland, was acquired by Mylan in 2010. Prior to Bioniche Pharma, Dan was vice president of product development for Abraxis BioScience (formerly American Pharmaceutical Partners Inc.) He also held leadership positions at Barr Laboratories, Inc. and scientific roles at Schering-Plough Research Institute, Mallinckrodt Veterinary and Pentech Pharmaceuticals. Dan received master’s and doctorate degrees in chemistry from The Ohio State University and his master’s degree in business administration from New York University. He earned his bachelor’s degree from LaSalle University.

Peter Strothman, Director

Peter Strothman has spent his career investing in the healthcare and private equity industries. He invests and creates value in companies specializing in life sciences, specialty pharmaceutical products and services, and general healthcare products and outsourced services. As a partner with Water Street, Peter has built a leading group of pharmaceutical companies. Prior to joining Water Street, Peter was a principal with JLL Partners, where he focused exclusively on healthcare investments. He began his career in the Global Mergers and Acquisitions group of Lehman Brothers. Peter received a bachelor’s degree in economics from Harvard University.

George Zorich, Director

George Zorich has more than 30 years of pharmaceutical industry experience. Most recently, he served as chief executive officer of Agilis Biotherapeutics, a company focused on developing a cure for Friedreich’s ataxia. Previously, George was president of Bioniche Pharmaceuticals, a manufacturer of branded and generic injectable products that was sold to Mylan Pharmaceuticals. George also was president of Sabex-USA, which was sold to Sandoz, where he led the Sandoz U.S. injectable business. Prior to that, he was president of GIV, which was the largest distributor of vaccines to physician offices. George also held executive positions at Fujisawa (now Astellas), Akorn Pharmaceuticals, Roxane Laboratories and Eli Lilly and Company. He is a board member of the American Society of HealthSystem Pharmacists Foundation and serves on the University of Wisconsin School of Pharmacy Board of Visitors. George received his pharmacy degree from the University of Wisconsin.